Abilify in adolescents

Use of Abilify (aripiprazole) in adolescents aged 15 years and above with schizophrenia has been approved. The recommended dose in this population is 10mg daily. Use of the drug to treat manic episodes in bipolar disorder remains not recommended under 18 years.

View Abilify drug record

Further information: Otsuka


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Prescribers alerted to topical steroid withdrawal reactions

Prescribers alerted to topical steroid withdrawal reactions

The MHRA has issued advice for prescribers to minimise...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Long-term antipsychotic use linked to breast cancer

Long-term antipsychotic use linked to breast cancer

Recent research indicates a significant increase in...